OSTX_OUT_1 [2025-04-02 09:15:50 -0400] 2814 Bytes | 754 tokens | Cum: 754 tkns (9.43% of 8k)
==========================================================================

We need a winner today and it's already 9:15:48 AM on Wed Apr 02, 2025 -0400 ... So let's find out if OS Therapies Incorporated (OSTX) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 1.5484 up from 1.33. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: OS Therapies Incorporated (OSTX)
IPO: 2024-08-01 (8 Months Ago)
Market Cap: $28,947,852
Shares Outstanding: 21,770,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XASE
Description: OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.

Here's the first list of news for OS Therapies Incorporated:

C1 - Today 07:40AM - OS Therapies to Host Analyst Day at NYSE on April 7, 2025
C2 - Mar-31-25 04:30PM - OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
C3 - Mar-31-25 04:30PM 07:40AM - OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
C4 - Mar-25-25 07:40AM - OS Therapies OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
C5 - Mar-23-25 08:49AM - OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts
C6 - Mar-21-25 07:40AM - OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
C7 - Mar-13-25 07:40AM - OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
C8 - Mar-11-25 07:40AM - OS Therapies Schedules United Kingdoms Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on OS Therapies Incorporated (OSTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

OSTX_OUT_3 [2025-04-02 09:16:02 -0400] 1099 Bytes | 298 tokens | Cum: 1054 tkns (13.18% of 8k)
==========================================================================

Showing C2 (chunk 1 of 11): C2:
**OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update**
Date: Mar-31-25 04:30PM
Source: (Business Wire)
URL: https://finance.yahoo.com/news/os-therapies-reports-full-2024-203000799.html

Full data from OST-HER2 Phase 2b osteosarcoma trial, including synthetic control arm data being developed at the request of FDA to support a Breakthrough Therapy Designation request, to be presented at MIB Factor in June 2025

Rolling BLA submission expected to begin thereafter in order to gain regulatory approval by year-end 2025, triggering issuance of a Priority Review Voucher (PRV)

NEW YORK, March 31, 2025--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX)("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial results ended December 31, 2024 and provided a bu

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OSTX_OUT_5 [2025-04-02 09:16:04 -0400] 380 Bytes | 87 tokens | Cum: 1272 tkns (15.90% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

OSTX_OUT_7 [2025-04-02 09:16:07 -0400] 267 Bytes | 67 tokens | Cum: 1342 tkns (16.78% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OSTX_OUT_9 [2025-04-02 09:16:09 -0400] 1098 Bytes | 275 tokens | Cum: 1619 tkns (20.24% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 8-K Item 2.02. Results of Oper and Fin Cond.

On March 31, 2025, OS Therapies Incorporated, a clinical-stage cancer immunotherapy and ADC biotechnology company, issued a press release announcing its financial results for the quarter and year ended December 31, 2024....

S2 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere...

S7 - 2025-01-29 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On January 28, 2025, OS Therapies Incorporated (OS Therapies or the Company) entered into an Asset Purchase Agrmt (the Purchase Agrmt) with Ayala Pharmaceuticals, Inc., a Delaware corporation formerly known as Advaxi...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OSTX_OUT_11 [2025-04-02 09:16:16 -0400] 912 Bytes | 229 tokens | Cum: 1850 tkns (23.12% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02. Results of Operations and Financial Condition.

On March 31, 2025, OS Therapies Incorporated, a clinical-stage cancer immunotherapy and ADC biotechnology company, issued a press release announcing its financial results for the quarter and year ended December 31, 2024.

A copy of the press release is furnished with this report as Exhibit 99.1. Such information, including Exhibit 99.1 attached hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OSTX_OUT_13 [2025-04-02 09:16:25 -0400] 4586 Bytes | 1262 tokens | Cum: 3264 tkns (40.80% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+----------------------+
| Volume: 108,700 | Perf Month: -7.64% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 1.18M | Perf Quarter: -74.22% | Short Float: 4.46% | ROE: - |
+--------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.09 | Index: - | Short Ratio: 0.54 | ROI: - |
+--------------------+-----------------------+------------------------+----------------------+
| RSI (14): 32.66 | Market Cap: 28.95M | Short Interest: 0.64M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.18 | Shs Outstand: 21.18M | Beta: - | EPS Surprise: -4.68% |
+--------------------+-----------------------+------------------------+----------------------+
| SMA20: -17.26% | Shs Float: 14.25M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+----------------------+
| SMA50: -28.98% | Inst Own: 0.67% | Sales past 5Y: - | Earnings: Mar 31 AMC |
+--------------------+-----------------------+------------------------+----------------------+
| SMA200: -53.72% | Insider Own: 34.55% | Employees: - | |
+--------------------+-----------------------+------------------------+----------------------+
| Perf Week: -16.35% | Insider Trans: -1.53% | Debt/Eq: - | |
+--------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: OS Therapies Inc (OSTX) by Romness Paul A. (President and CEO) on 2025-02-28
- Common Stock, par value $0.001 per share: 225000 shares at $0 (D)

Inside Trans: OS Therapies Inc (OSTX) by Auerbach Shalom (Unknown Title) on 2025-02-27
- Common Stock, par value $0.001 per share: 225000 shares at $1.64 (I) Footnote: Forfeiture of shares of Common Stock that were held in escrow pursuant to a Transfer Agreement that Einodmil entered into on May 13, 2024. The shares of Common Stock were forfeited pursuant to the terms and conditions of the Transfer Agreement.

Inside Trans: OS Therapies Inc (OSTX) by Auerbach Shalom (Unknown Title) on 2025-02-14
- Common Stock, par value $0.001 per share: 100000 shares at $2.843 (I)

No transactions recorded.

Inside Trans: OS Therapies Inc (OSTX) by Auerbach Shalom (Unknown Title) on 2025-01-15
- Common Stock, par value $0.001 per share: 16720 shares at $6.735 (I)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -2875232.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.33
Average Volume: 118678.41
30-Day High: 1.73
30-Day Low: 1.33

[Detailed Financials: Q3 2024]
- Total Assets: $1,977,264.0
- Total Liabilities: $2,684,391.0
- Total Equity: $-707,127
- Current Assets: $1,970,604.0
- Current Liabilities: $2,584,391.0

[Income Statement: Q3 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.18

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

OSTX_OUT_15 [2025-04-02 09:16:29 -0400] 676 Bytes | 167 tokens | Cum: 3629 tkns (45.36% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

OSTX_IN_17 [2025-04-02 09:16:29 -0400] 126 Bytes | 29 tokens | Cum: 3753 tkns (46.91% of 8k)
==========================================================================

====================================
[2025-04-02 09:16:29] # Analysis Completed
Elapsed Time: 41.76 seconds